Want to see GEHC full AI Analyst Report?
Top Page
GE Healthcare Technologies Inc
(NASDAQ:GEHC)
Select Model
Select Model
Rating:60Neutral
Price Target:
$68.00
▼(-7.24% Downside)
Action:Reiterated
Date:09/23/26
The score is driven mainly by steady-but-not-accelerating fundamentals: profitability is intact but margins and free cash flow have weakened, keeping financial performance mid-range. The earnings call supports the outlook with reaffirmed guidance and strong order/backlog indicators, but execution risks (PCS weakness, inflation, and cash volatility) remain. Technically, the stock trend is weak with bearish momentum, while valuation is reasonable but not strongly supported by yield.
Positive Factors
Record backlog and demand visibility
Strong order growth, a book-to-bill ratio above one, and a record backlog provide meaningful forward revenue visibility. These indicators suggest continued customer demand and support more predictable equipment activity over the next several quarters, despite uneven segment performance.
Negative Factors
Patient Care Solutions structural weakness
The strategic review and negative profitability indicate that Patient Care Solutions is more than a minor quarterly issue. A potential sale or restructuring could require management attention, disrupt the portfolio, and leave GE HealthCare dependent on successful recovery actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Record backlog and demand visibility
Strong order growth, a book-to-bill ratio above one, and a record backlog provide meaningful forward revenue visibility. These indicators suggest continued customer demand and support more predictable equipment activity over the next several quarters, despite uneven segment performance.
Read all positive factors
GE Healthcare Technologies Inc Key Performance Indicators (KPIs)
Any
Remaining Performance Obligations by Type
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Data provided by:
The Fly
The FlyGE Healthcare Technologies Inc (GEHC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.04B
Dividend Yield0.22%
Average Volume (3M)3.19M
Price to Earnings (P/E)18.5
Beta (1Y)1.36
Revenue Growth6.52%
EPS Growth-11.06%
CountryUS
Employees54,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)3.48
Shares Outstanding451,686,250
10 Day Avg. Volume3,987,064
30 Day Avg. Volume3,186,616
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda10.86
Forecast
1Y Price Target
$80.00Price Target Upside9.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.92
Revenue Forecast (FY)$21.72B
GE Healthcare Technologies Inc Business Overview & Revenue Model
Company Description
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis,...
How the Company Makes Money
GEHC primarily makes money by selling healthcare equipment, related consumables, and services to providers and other healthcare customers, with revenue generally coming from three major areas: (1) Capital equipment and associated software: GEHC se...
GE Healthcare Technologies Inc Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.Positive Updates
Record Orders, Backlog and Book-to-Bill
Organic orders growth of 11.1% (quarterly), book-to-bill of 1.15x (highest since spin), and record backlog of $23.9 billion, up $2.6 billion year-over-year and $2.1 billion sequentially.
Negative Updates
Patient Care Solutions (PCS) Weakness
PCS organic revenue declined 13.5% year-over-year and segment EBIT was negative due to operational fulfillment and supply issues; management expects improvement in the second half but the segment materially pressured company margins in the quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Orders, Backlog and Book-to-Bill
Organic orders growth of 11.1% (quarterly), book-to-bill of 1.15x (highest since spin), and record backlog of $23.9 billion, up $2.6 billion year-over-year and $2.1 billion sequentially.
Read all positive updates
Company Guidance
GE HealthCare reaffirmed its 2026 guidance, calling for 3%–4% organic sales growth, 10–40 bps of adjusted EBIT margin expansion to a 15.4%–15.7% range, adjusted EPS of $4.80–$5.00 (roughly 5%–9% y/y growth) and about $1.6 billion of free cash flow; for Q3 it expects 3%–4% organic revenue growth and low‑double‑digit adjusted EPS growth y/y. Management said H2 should see a meaningful margin step‑up (over 300 bps of expansion from H1 to H2 driven by price, cost actions and higher‑margin NPIs), cited a secured equipment rate entering Q3 of >80% (nearly 85%), and pointed to book‑to‑bill of 1.15x and a record $23.9 billion backlog as supports. The company also reiterated medium‑term targets: mid‑single‑digit organic growth, high‑teens to ~20% adjusted EBIT margin, high‑single‑digit to low‑double‑digit EPS growth, ~90% FCF conversion, and a Flyrcado goal of $500M+ annual revenue by 2028.GE Healthcare Technologies Inc Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.24B | 20.63B | 19.67B | 19.55B | 18.34B | 17.59B |
| Gross Profit | 8.69B | 8.25B | 8.21B | 7.92B | 7.18B | 7.17B |
| EBITDA | 3.48B | 3.79B | 3.67B | 3.51B | 3.17B | 3.54B |
| Net Income | 1.59B | 2.08B | 1.99B | 1.57B | 1.92B | 2.25B |
Balance Sheet | ||||||
| Total Assets | 37.25B | 36.91B | 33.09B | 32.45B | 27.54B | 26.31B |
| Cash, Cash Equivalents and Short-Term Investments | 2.10B | 4.51B | 2.89B | 2.50B | 1.45B | 556.00M |
| Total Debt | 10.09B | 10.00B | 9.38B | 9.86B | 8.63B | 437.00M |
| Total Liabilities | 26.26B | 26.31B | 24.44B | 25.14B | 17.95B | 9.41B |
| Stockholders Equity | 10.97B | 10.38B | 8.45B | 7.13B | 9.36B | 16.66B |
Cash Flow | ||||||
| Free Cash Flow | 895.00M | 1.51B | 1.55B | 1.71B | 1.80B | 1.36B |
| Operating Cash Flow | 1.42B | 1.99B | 1.95B | 2.10B | 2.11B | 1.61B |
| Investing Cash Flow | -3.03B | -1.05B | -914.00M | -558.00M | -398.00M | -1.76B |
| Financing Cash Flow | -883.00M | 617.00M | -573.00M | -478.00M | -822.00M | -263.00M |
GE Healthcare Technologies Inc Technical Analysis
Negative
73.31
Price Trends
68.72
Negative
66.11
Negative
71.23
Negative
Market Momentum
-1.01
Negative
37.50
Neutral
23.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Negative. The current price of 73.31 is above the 20-day moving average (MA) of 65.32, above the 50-day MA of 68.72, and above the 200-day MA of 71.23, indicating a bearish trend. The MACD of -1.01 indicates Negative momentum. The RSI at 37.50 is Neutral, neither overbought nor oversold. The STOCH value of 23.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GEHC.
GE Healthcare Technologies Inc Risk Analysis
GE Healthcare Technologies Inc disclosed 32 risk factors in its most recent earnings report. GE Healthcare Technologies Inc reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GE Healthcare Technologies Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $49.08B | 48.94 | 9.69% | ― | 14.55% | 15.09% | |
77 Outperform | $110.49B | 21.12 | 10.60% | 3.31% | 9.77% | 12.28% | |
73 Outperform | $168.71B | 31.35 | 10.52% | 2.54% | 8.06% | -61.33% | |
69 Neutral | $61.74B | 17.18 | 14.90% | ― | 13.53% | 46.29% | |
60 Neutral | $29.04B | 18.47 | 15.16% | 0.22% | 6.52% | -11.06% | |
58 Neutral | $23.28B | 18.18 | 10.05% | 4.14% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GEHC
GE Healthcare Technologies Inc
64.29
-11.97
-15.70%
ABT
Abbott Laboratories
97.50
-33.22
-25.41%
BSX
Boston Scientific
42.60
-54.10
-55.95%
EW
Edwards Lifesciences
85.15
8.59
11.22%
PHG
Koninklijke Philips
23.92
-3.23
-11.88%
MDT
Medtronic
86.38
-8.89
-9.33%
GE Healthcare Technologies Inc Corporate Events
Executive/Board ChangesRegulatory Filings and Compliance
GE HealthCare Appoints Pascal Desroches to Board Committees
Positive
Sep 22, 2026
On September 22, 2026, GE HealthCare Technologies Inc. announced that its Board of Directors has appointed Pascal Desroches as a director, effective January 4, 2027. He will join both the Audit Committee and the Talent, Culture, and Compensation C...
Business Operations and StrategyExecutive/Board Changes
GE HealthCare Appoints William Grogan as New CFO
Positive
Aug 18, 2026
On August 13, 2026, GE HealthCare Technologies Inc. appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026, succeeding interim CFO George A. Newcomb, who will return full-time to his roles as Controller and Chief Acco...
Business Operations and StrategyFinancial Disclosures
GE HealthCare unveils new Advanced Imaging Solutions segment
Positive
Jul 29, 2026
In the second quarter of 2026, GE HealthCare reorganized its operations by combining its Imaging and Advanced Visualization Solutions businesses into a new Advanced Imaging Solutions segment, alongside Pharmaceutical Diagnostics and Patient Care S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.